Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients.
BACKGROUND: Cytomegalovirus infection in renal transplant recipients is a major clinical problem, with both short and long term sequelae. Infection can occur as a result of reactivation of latent virus or new infection from donor tissues. The impact of donor and recipient serostatus on viremia is w...
Autors principals: | Hughes, D, Hafferty, J, Fulton, L, Friend, P, Devaney, A, Loke, J, Welsh, K, Handa, A, Klenerman, P |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
2008
|
Ítems similars
-
How Do Donor-recipient CMV Serostatus and Post-hematopoietic Stem Cell Transplantation CMV Reactivation Affect Outcomes in Acute Leukemia Patients?
per: Mohammad Vaezi, et al.
Publicat: (2016-10-01) -
CMV infection of liver transplant recipients: comparison of antigenemia and molecular biology assays
per: Castro Ana, et al.
Publicat: (2001-05-01) -
Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients
per: Jumpei Hasegawa, et al.
Publicat: (2017-12-01) -
QuantiFERON CMV Test and CMV Serostatus in Lung Transplant: Stratification Risk for Infection, Chronic and Acute Allograft Rejection
per: Paolo Solidoro, et al.
Publicat: (2024-08-01) -
Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
per: Reddy, S, et al.
Publicat: (2003)